A new case of t(16;21)(q24;q22) in a secondary AML-M2 following breast cancer therapy

Hélène Bruyère, Wilson Yeung, Peter Tsang Affiliation

Department of Pathology and Laboratory Medicine, Vancouver General Hospital, UBC, Canada, Helene.Bruyere@vch.ca and Division of Hematology, Vancouver General Hospital, UBC, Canada

Previous history

Preleukaemia

Malignant disease

Breast cancer diagnosed in 2002, treated with radical mastectomy, chemotherapy with cyclophosphamide, epirubicin, 5-fluoro-uracil, radiotherapy.

Inborn condition

Clinics case report

Age

61 yrs

Sex

Liver

Spleen

Lymph nodes

Cns involv

Blood data

Wbc

2.4

10.7

Platelets

Blasts

Bone marrow

Neutrophils 0.05 ; Band cells 0.05 ; Metamyelocytes 0.13 ; Myelocytes 0.02 ; Promyelocytes 0.02 ; Blasts 0.51 ; Late normoblasts 0.13 ; Plasma cells 0.01 ; Lymphocytes 0.05 ; Monocytes 0.01 ; Eosinophils 0.02

Cyto path

Cytology

AML-M2

Immunophenotype

Positive for HLA-DR, CD34, CD117, CD13, CD33, MPO, CD56 and CD19 ; Partial Tdt ; Negative for CD7

Precise diagnosis

Hypoplastic AML, therapy related

Survival data

Date diagnosis

04-2005

Treatment

Three cycles of AraC and Danuribicin ; Related bone marrow transplantation planned for September 2005

Complete remission

Yes, 05-2005

Status

Date last follow

07-2005

Survival

3 +

Karyotype

Sample

Bone marrow

Culture time

Banding

GTG

Results

47,XX,+8,t(16;21)(q24;q22)[13]/46,XX[3]

Images

Partial karyotype showing the t(16;21) and a +8

Comments section

Comments

All of the nine patients whose treatments were reported (3-9), plus the current case, were treated with a combination of alkylating agents and topoisomerase II inhibitors, +/- radiotherapy.

Article Bibliography

Pubmed ID	Last Year	Title	Authors
2758395	1989	Cytogenetics of childhood acute nonlymphocytic leukemia.	Raimondi SC et al
7819102	1994	Metaphase fluorescence in situ hybridization (FISH) in the follow-up of 60 patients with haemopoietic malignancies.	Nylund SJ et al
8043877	1994	Clonal karyotypic hematopoietic cell abnormalities occurring after autologous bone marrow transplantation for Hodgkin's disease and non-Hodgkin's lymphoma.	Traweek ST et al
8932000	1996	Secondary acute myeloblastic leukemia with t(16;21) (q24;q22). involving the AML1 gene.	Berger R et al
9216714	1997	A recurrent translocation, t(16;21)(q24;q22), associated with acute myelogenous leukemia: identification by fluorescence in situ hybridization.	Shimada M et al
9631585	1998	A case of therapy-related acute myeloblastic leukemia with t(16;21)(q24;q22) after chemotherapy with DNA-topoisomerase II inhibitors, etoposide and mitoxantrone, and the alkylating agent, cyclophosphamide.	Takeda K et al
10995019	2000	AML1-MTG16 fusion gene in therapy-related acute leukemia with t(16;21)(q24;q22): two new cases.	Salomon-Nguyen F et al
11224496	2001	AML1/MTG16 fusion gene from a t(16;21)(q24;q22) translocation in treatment-induced leukemia after breast cancer.	La Starza R et al
11999578	2002	A pediatric case of secondary leukemia associated with t(16;21)(q24;q22) exhibiting the chimeric AML1-MTG16 gene.	Kondoh K et al
11921272	2002	21q22 balanced chromosome aberrations in therapy-related hematopoietic disorders: report from an international workshop.	Slovak ML et al

Citation

Hélène Bruyère, Wilson Yeung, Peter Tsang

A new case of t(16;21)(q24;q22) in a secondary AML-M2 following breast cancer therapy

Atlas Genet Cytogenet Oncol Haematol. 2005-08-01

Online version: http://atlasgeneticsoncology.org/case-report/208811/js/favicon/css/template-main.css